<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Health economics Healthcare quality Immunosuppressants Orphan drugs Costs Disease-modifying antirheumatic drug Tocilizumab Rituximab Quality-adjusted life year Rheumatoid arthritis Etanercept TNF inhibitor |
Add to Reading List |
TOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | TOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS REPORT BY THE DECISION SUPPORT UNIT Stephen Palmer, Mark SculpherDocID: 1s1AX - View Document |
 | NOVEMBER 2015 TABLE OF CONTENTS INTRODUCTIONDocID: 1qUAB - View Document |
| TOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITISDocID: 1pnYX - View Document |
 | JULY 2016 TABLE OF CONTENTS INTRODUCTIONDocID: 1pejO - View Document |
 | TABLE OF CONTENTS INTRODUCTION 2DocID: 1oMip - View Document |